PRIMER-SWITCH
Live / Allowed — Notice of allowance issued (as of 30 Dec 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 14 Nov 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98853682
- Mark type
- Stylized text
- Filed
- 14 Nov 2024
- Published for opposition
- 04 Nov 2025
- Attorney of record
- Barry F. Soalt
Goods and services
- Class 005 — Pharmaceuticals: Medical diagnostic reagents and assays for testing of bodily fluids for use in detection of any disease or condition where it is desired to detect specific nucleic acids or derivatives thereof, namely, cancer, infectious disease, inherited genetic disease, somatic aberration, and rejection of transplanted organs; drug testing kits comprised of medical diagnostic reagents and assays that test for the presence of gene events, namely, mutations, single nucleotide polymorphisms (SNP's) and other disease biomarkers, translocations, deletions, gene copy number changes, RNA expression levels, and biomarkers specific to disease conditions; drug testing kits comprised of medical diagnostic reagents and assays, test strips, test patches, and test media for testing of bodily fluids for use in detection of any disease or condition where it is desired to detect specific nucleic acids or derivatives thereof, namely, cancer, infectious disease, inherited genetic disease, somatic aberration, and rejection of transplanted organs
- Class 010 — Medical apparatus: Medical diagnostic apparatus and instruments for testing DNA and RNA and for diagnostic testing for the interrogation of DNA and RNA nucleic acids for any disease or condition where it is desired to detect specific nucleic acids or derivative thereof, namely, cancer, an infectious disease, inherited genetic disease, somatic aberration, and rejection of transplanted organs
- Class 042 — Scientific and technological services: Medical, scientific and clinical research in the fields of diagnostics, genomics, next generation sequencing (NGS) and therapeutics, molecular diagnostics for the detection of DNA and RNA targets of interest, Sanger sequencing, NGS, capillary electrophoresis, mass-spectral analysis, and microarray analysis
- Class 044 — Medical, beauty and agricultural services: Health assessment services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; and consulting services in the fields of diagnostic medical testing and treatment of diseases
Owner
- Aegea Biotechnologies, Inc., Poway, CA, US
- Aegea Biotechnologies, Inc., Poway, CA, US
Prosecution history
- 30 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Nov 2025 — PUBLISHED FOR OPPOSITION
- 29 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 06 Oct 2025 — EXAMINER'S AMENDMENT ENTERED
- 06 Oct 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 06 Oct 2025 — EXAMINERS AMENDMENT E-MAILED
- 06 Oct 2025 — EXAMINERS AMENDMENT -WRITTEN
- 13 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 16 May 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 16 May 2025 — NON-FINAL ACTION E-MAILED
- 16 May 2025 — NON-FINAL ACTION WRITTEN